(Q33603346)

28 July 2017

1 reference

title

Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan (English)

1 reference

28 July 2017

0 references

0 references

0 references

0 references

visceral leishmaniasis

1 reference

0 references

2

Kishor M Wasan

1 reference

28 July 2017

Sheila J Thornton

1

1 reference

28 July 2017

Anna Piecuch

series ordinal

3

1 reference

28 July 2017

Larry L D Lynd

series ordinal

4

1 reference

28 July 2017

Ellen K Wasan

series ordinal

5

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

Drug Development and Industrial Pharmacy

28 July 2017

1 reference

28 July 2017

36

1 reference

28 July 2017

11

1 reference

28 July 2017

1312-1319

1 reference

Characterization and speculations on the urbanization of visceral leishmaniasis in Brazil

28 July 2017

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Role of the domestic dog as a reservoir host of Leishmania donovani in eastern Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Drug regimens for visceral leishmaniasis in Mediterranean countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Drug resistance in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

The economic impact of visceral leishmaniasis on households in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

The organization of health services and visceral leishmaniasis: an integrated intervention to improve diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

The giant anteater in the room: Brazil's neglected tropical diseases problem

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Paying for hospital-based care of Kala-azar in Nepal: assessing catastrophic, impoverishment and economic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

The economic burden of visceral leishmaniasis for households in Nepal.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Kala-azar epidemiology and control, southern Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Accessibility of diagnostic and treatment centres for visceral leishmaniasis in Gedaref State, northern Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Leishmaniasis and poverty

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Treatment of leishmaniasis with miltefosine: 2008 status

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

Highly effective oral amphotericin B formulation against murine visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639041003796648

10.3109/03639041003796648

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference